ATG4B and osteosarcoma: NSC185058 effectively inhibited ATG4B activity in vitro and in cells while having no effect on MTOR and PtdIns3K activities. ATG4B antagonist had a negative impact on the development of Saos-2 osteosarcoma tumors in vivo [117].